What You Should Know
- Care management and utilization management technology provider Elligint Health announced that it has acquired conversational AI company Laguna Health.
- Laguna Health will operate as a wholly owned subsidiary of Elligint Health, retaining its brand, product suite, website, and leadership under co-founder and CEO Yoni Shtein.
- The acquisition unites Laguna’s conversational AI capabilities with Elligint Health’s Helios® care and utilization management platform, which serves more than 13 million managed lives across all 50 states.
- Laguna’s product portfolio addresses every stage of member engagement through Laguna Companion (an AI co-pilot for pre-call preparation, live call support, and automated post-call documentation), Laguna Insight (a quality assurance engine that audits 100% of member calls against plan-specific clinical standards), and LISA (an agentic AI assistant for autonomous member outreach, assessment, and warm handoffs).
Ambient Co-Pilots, Full-Population Audits, and Agentic Outreach
Founded in 2020 by Yoni Shtein and Yael Peled Adam with operations in Edison, New Jersey, and Tel Aviv, Laguna Health built its platform specifically around the operational workflows of front-line health plan staff. Rather than offering a generic transcription tool, the company deploys three specialized artificial intelligence engines that govern the entire lifecycle of member engagement.
At the center of live clinical calls is Laguna Companion, an artificial intelligence co-pilot that synthesizes member context to prepare care managers prior to outreach, surfaces real-time clinical prompts during the conversation, and automates structured post-call charting. Alongside the co-pilot sits Laguna Insight, an automated quality assurance engine—recognized among TIME’s Best Inventions of 2024—that evaluates 100 percent of member conversations against a health plan’s proprietary clinical protocols rather than relying on manual spot-checks. Completing the product suite is LISA, an agentic artificial intelligence assistant designed to execute autonomous outbound member outreach, conduct standardized health assessments, and execute warm handoffs to human care managers when clinical complexity requires human intervention.
Clinical Validation and Commercial Deployment Flexibility
Unlike early-stage generative artificial intelligence vendors still seeking production proof points, Laguna enters the Elligint ecosystem with established clinical and operational validation. The platform documents member conversations with 99 percent clinical content accuracy and is supported by a peer-reviewed randomized controlled trial published in the Journal of Healthcare Management. In a published customer deployment, a multi-state health plan reduced care manager documentation time by 66 percent, freeing substantial clinical capacity for complex case management.
A defining feature of the acquisition is its non-disruptive deployment architecture. Health plans can adopt Laguna’s tools as standalone modules inside their existing third-party care management platforms with zero upfront integration required to go live, or deploy them natively alongside Elligint’s Helios ecosystem. Over the coming quarters, Elligint plans to deepen native product integrations between Helios and Laguna’s engines—beginning with Laguna Companion—while preserving independent commercial availability for plans operating on competing core administrative systems.
“Health plans want AI that helps care teams in their daily work, and they want proof that it’s accurate and safe,” said Chris Caramanico, Chief Executive Officer of Elligint Health. “Laguna has that proof today. It’s a safe, low-risk, high-return use of AI, proven with health plans. It works inside the systems plans already use, and each plan stays in full control, with Laguna configured to its own workflows and protocols. Helios runs the work. Laguna makes every conversation count. Together, we can bring AI into care management either company could alone.”
